Skip to main content

Table 2 Safety of gemfibrozil in children

From: Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders

Age Dose (duration) Purpose Effect Side effects (reference)
Children with metabolic Syndrome, n = 47 600 mg 2 x /day (8 months) reduce lipids ↓triglycerides
↑HDL
1AE muscle pain n = 2 (52)
Late preterm & term neonates with jaundice n = 97 (49 active, 48 placebo) 60 mg/kg 2 doses (1 day) reduce light therapy time, decrease bilirubin no effect none
(51)
Infants with Chylomicronemia* Syndrome, n = 2 300 mg 2 x /day (3, 7 years) improve jaundice ↓pancreatitis none (54)
Children with hyperlipidemia & nephrotic syndrome, n=12 (7 active, 5 placebo) 150 mg 2 x/day (4 months) reduce lipids ↓cholesterol ↓triglycerides none (50)
Age 13 female n = 1 3 weeks reduce lipids NA LABD (55)
  1. *Siblings started gemfibrozil at birth and at 6 months, respectively
  2. LABD, linear IgA bullous dermatitis